Insider Transactions in Q1 2021 at Aerie Pharmaceuticals Inc (AERI)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 23
2021
|
Vicente Anido Jr Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,700
-0.72%
|
$25,500
$15.66 P/Share
|
|
Feb 23
2021
|
Casey C. Kopczynski Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
328
-0.12%
|
$4,920
$15.66 P/Share
|
|
Feb 23
2021
|
Thomas A Mitro President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
763
-0.87%
|
$11,445
$15.66 P/Share
|
|
Feb 23
2021
|
Richard J Rubino Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
410
-0.12%
|
$6,150
$15.66 P/Share
|
|
Feb 19
2021
|
John La Rocca General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,542
-3.67%
|
$23,130
$15.95 P/Share
|
|
Feb 15
2021
|
Casey C. Kopczynski Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
725
-0.27%
|
$11,600
$16.41 P/Share
|
|
Feb 15
2021
|
Casey C. Kopczynski Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
60,651
+18.59%
|
$0
$0.2 P/Share
|
|
Feb 08
2021
|
Richard J Rubino Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
921
-0.26%
|
$15,657
$17.72 P/Share
|
|
Feb 08
2021
|
Thomas A Mitro President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,085
-1.23%
|
$18,445
$17.72 P/Share
|
|
Feb 08
2021
|
Casey C. Kopczynski Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
666
-0.32%
|
$11,322
$17.72 P/Share
|
|
Feb 08
2021
|
Vicente Anido Jr Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,500
-1.05%
|
$42,500
$17.72 P/Share
|
|
Feb 07
2021
|
Richard J Rubino Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,075
-0.3%
|
$18,275
$17.68 P/Share
|
|
Feb 07
2021
|
Thomas A Mitro President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,229
-1.37%
|
$20,893
$17.68 P/Share
|
|
Feb 07
2021
|
John La Rocca General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
706
-1.65%
|
$12,002
$17.68 P/Share
|
|
Feb 07
2021
|
Casey C. Kopczynski Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
701
-0.34%
|
$11,917
$17.68 P/Share
|
|
Feb 07
2021
|
Vicente Anido Jr Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,496
-1.04%
|
$42,432
$17.68 P/Share
|
|
Feb 06
2021
|
Richard J Rubino Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,185
-0.33%
|
$20,145
$17.68 P/Share
|
|
Feb 06
2021
|
Thomas A Mitro President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,438
-1.58%
|
$24,446
$17.68 P/Share
|
|
Feb 06
2021
|
John La Rocca General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
353
-0.82%
|
$6,001
$17.68 P/Share
|
|
Feb 06
2021
|
Casey C. Kopczynski Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
876
-0.42%
|
$14,892
$17.68 P/Share
|
|
Feb 06
2021
|
Vicente Anido Jr Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,958
-1.22%
|
$50,286
$17.68 P/Share
|
|
Feb 04
2021
|
Vicente Anido Jr Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,000
+10.33%
|
-
|
|
Feb 04
2021
|
Richard J Rubino Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+3.25%
|
-
|
|
Feb 04
2021
|
Thomas A Mitro President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+13.3%
|
-
|
|
Feb 04
2021
|
John La Rocca General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+20.36%
|
-
|
|
Feb 04
2021
|
Casey C. Kopczynski Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+5.04%
|
-
|
|
Feb 04
2021
|
David Hollander Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+24.53%
|
-
|